Praxis Dr. Toursarkissian
- Address
- Heinz-Galinski-Straße 1, 13347 Berlin, Germany
Praxis Dr. Toursarkissian - Lipid Metabolism & Cardiovascular Risk Management
Praxis Dr. Toursarkissian is a specialized clinical research center focused on advancing therapeutic approaches for patients with lipid disorders and cardiovascular disease risk. The practice demonstrates particular expertise in evaluating novel lipid-lowering therapies and their impact on patient outcomes, with emphasis on achieving optimal cholesterol targets in high-risk populations.
- Hypercholesterolemia management and LDL-cholesterol reduction strategies
- Innovative biologic therapies including PCSK9 inhibitors
- Cardiovascular risk reduction through personalized lipid-lowering treatment optimization
The center's research portfolio includes pivotal studies examining the efficacy and safety of inclisiran, a novel RNA-based therapy, in combination with existing lipid-lowering treatments. This work contributes to establishing evidence-based approaches for patients requiring intensive cholesterol management to meet guideline-recommended LDL-C targets below 55 mg/dL or 70 mg/dL, representing critical thresholds for secondary prevention in cardiovascular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 1 therapeutic areas and 15 of 23 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praxis Dr. Toursarkissian
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of XXB750 in Heart Failure Patients with LVEF < 50% on Standard Care Including ACEI/ARB or Sacubitril/Valsartan | Novartis Pharma AG | Phase II | Not Recruiting | Mar 2024 | Nov 2024 |
IMP list
lock Showing 1 of 23 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Azilsartan Medoxomil | 1 | Unknown | 2024-03-13 | 2024-03-13 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.